LexisNexis® Legal Newsroom
Fulbright's Litigation Trends Survey: Companies Expect More Litigation, Regulation

NEW YORK - (Business Wire) Following a year of doing business in a more litigious and cost-conscious environment, companies of all sizes expect those patterns to continue during the coming year, with roughly one-quarter saying legal disputes will increase again, according to Fulbright's 7th Annual...

Barroway Topaz Launches Patent Litigation Practice, Adds Patent Trial Lawyers

RADNOR, Pa. - Leading plaintiffs' shareholder and corporate governance law firm Barroway Topaz Kessler Meltzer & Check LLP has added a patent litigation platform and brought in two established intellectual property lawyers to direct the initiative. The firm announced that noted patent litigators...

Wilson Sonsini Goodrich & Rosati Expands IP Litigation Practice

PALO ALTO, Calif. - Wilson Sonsini Goodrich & Rosati, the premier provider of legal services to technology, life sciences, and growth enterprises worldwide, is pleased to announce that Jeffrey Alan Hovden has become a partner at the firm. An experienced intellectual property litigator and counselor...

Troutman Sanders LLP: Jury Awards ActiveVideo $115 Million From Verizon In Patent Litigation

By Joshua Heslinga Late yesterday, a jury awarded ActiveVideo $115 million from Verizon, concluding the trial phase of the heated patent litigation. The Virginian Pilot reports on the verdict, and here is the verdict form . Our prior blog entries on this case (E.D. Va. no. 2:10-cv-00248) are here...

Patent Actions On The Rise, Median Damages Awarded Hits 16-Year Low, According To Patent Litigation Study

NEW YORK - Reflecting upon developments currently underway in patent reform legislation, PwC US on Oct. 18 released a new report "2011 Patent Litigation Study: Patent litigation trends as the 'America Invents Act' becomes law" summarizing trends in the patent infringement litigation...

Troutman Sanders LLP: Is Multidistrict Patent Litigation The Next Frontier?

By Robert Angle On January 26, 2012, Bear Creek Technologies, Inc. ("Bear Creek") filed a Notice of Filing Motion for Multi-District Litigation pursuant to 28 U.S.C. § 1407, in Bear Creek Technologies, Inc. v. RCN Telecom Services, LLC, Civil Action No.: 2:11-cv-103 (RAJ/FBS). This...

New Patent Reform Bill Seeks To Recover Costs Of 'Egregious Legal Disputes'

Since the enactment of the America Invents Act (AIA) in September of 2011, the "patent reform" embodied by the AIA has been slowly rolling out. In fact, the bulk of the truly significant changes to patent law are still to come. These changes include the change over to the first inventor to...

High Court Will Consider Whether Reverse-Payment Settlements Are Anti-Competitive

WASHINGTON, D.C. — (Mealey's) The Supreme Court on Dec. 7 granted the Federal Trade Commission’s petition for a writ of certiorari seeking consideration of whether reverse-payment settlements of patent litigation between the holder of a drug patent and generic manufacturers of the drug...

Reverse-Payment Settlements Presumptively Anticompetitive, FTC Tells High Court

WASHINGTON, D.C. - (Mealey's) The Federal Trade Commission told the U.S. Supreme Court in oral arguments March 25 that the court should treat reverse-payment settlements of patent litigation between the holder of a drug patent and potential generic manufacturers of the drug as presumptively invalid...

Supreme Court Partly Reverses, Says Isolated DNA Not Patentable

WASHINGTON, D.C. - (Mealey's) In a unanimous ruling June 13, the U.S. Supreme Court found that although complementary DNA, or "cDNA," is patent-eligible, isolated DNA is not ( The Association for Molecular Pathology, et al. v. Myriad Genetics Inc. , No. 12-398, U.S. Sup.). (lexis.com subscribers...

High Court: Reverse-Payment Settlements Are Not Immune From Antitrust Scrutiny

WASHINGTON, D.C. - (Mealey's) The U.S. Supreme Court on June 17 ruled 5-3 that reverse-payment settlements of patent litigation between the holder of a drug patent and potential generic manufacturers of the drug are not necessarily immunized from an antitrust challenge, even if the anti-competitive...